AI-generated summary
The authors studied ruthenium phthalocyanine compounds in human melanoma (A375) cells exposed to light. They report that light at 660 nm reduced viable cells to around 50% with one compound, and that adding 850 nm photobiomodulation increased photocytotoxicity, which they attribute to higher ATP production and compound uptake. These are cell-culture findings, so their relevance to patients is unclear.
- Who or what was studied
- A375 human melanoma cells in vitro
- Wavelengths
- 660, 850 nm
- Limits stated in the abstract
- The study uses cultured cells rather than people or animals, and the abstract offers only a mechanistic interpretation (hypothesized synergy and attributed effects).
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm, 850 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photodynamic therapy, Photobiomodulation, Adenosine triphosphate, Nitric oxide, Reactive oxygen species. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.